Literature DB >> 23385097

Determination of organ-specific anemia tolerance.

Patrick Lauscher1, Harry Kertscho, Olga Schmidt, René Zimmermann, Peter Rosenberger, Kai Zacharowski, Jens Meier.   

Abstract

OBJECTIVE: Utilization of anemia tolerance reduces the need for and risks of perioperative transfusion. Recent publications indicate that the critical limit for oxygen supply might not be the same for each organ system. Therefore, we investigated the effects of acute dilutional anemia on heart, brain, kidneys, liver, small intestine, and skeletal muscle to quantify organ-specific tolerance of different levels of acute anemic hypoxia. We hypothesized that, in some organs, tissue hypoxia occurs before the critical limits of systemic oxygen supply are reached.
DESIGN: Laboratory animal experiments.
SETTING: Animal research laboratory at university medical school.
SUBJECTS: A total of 18 domestic pigs of either sex (average weight: 19.6 kg).
INTERVENTIONS: Animals were anesthetized, ventilated, and randomized into three groups and then hemodiluted by exchange of 6% hydroxyethyl starch (130,000:0.4) for whole blood to the group-specific endpoint: Sham (no hemodilution), Hb4 (hemoglobin 4.3 g/dL), Hbcrit (2.7 g/dL). Subsequently, 10 mg/kg pimonidazole (which forms protein adducts in hypoxic cells) was injected. One hour after injection, tissue samples were collected and analyzed for pimonidazole-protein adduct quantification (dot blot) and as a surrogate for transcriptional activation during hypoxia the expression of vascular endothelial growth factor messenger RNA. Relevant hemodynamic and metabolic parameters were collected.
MEASUREMENTS AND MAIN RESULTS: Hemodynamics, metabolic parameters, or oxygen consumption did not indicate that tissue oxygenation was restricted before reaching Hbcrit. However, kidneys and skeletal muscle showed enhanced pimonidazole binding and vascular endothelial growth factor expression at Hb4. By contrast, liver oxygenation was actually improved at Hb4. Heart, brain, and liver showed no signs of tissue hypoxia at Hb4.
CONCLUSIONS: Heart, brain, kidneys, liver, small intestine, and skeletal muscle experience tissue hypoxia at different degrees of acute anemia, as assessed by the pimonidazole method and vascular endothelial growth factor expression. Further studies are needed to elucidate the mechanisms that determine organ-specific anemia tolerance.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23385097     DOI: 10.1097/CCM.0b013e3182746423

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  6 in total

Review 1.  [Patient Blood Management : three pillar strategy to improve outcome through avoidance of allogeneic blood products].

Authors:  H Gombotz; A Hofmann
Journal:  Anaesthesist       Date:  2013-07       Impact factor: 1.041

Review 2.  RBC Transfusion Triggers: Is There Anything New?

Authors:  Tina Tomic Mahecic; Martin Dünser; Jens Meier
Journal:  Transfus Med Hemother       Date:  2020-09-24       Impact factor: 3.747

Review 3.  Epidemiology of Necrotizing Enterocolitis: New Considerations Regarding the Influence of Red Blood Cell Transfusions and Anemia.

Authors:  Vivek Saroha; Cassandra D Josephson; Ravi Mangal Patel
Journal:  Clin Perinatol       Date:  2018-12-12       Impact factor: 3.430

Review 4.  Evidence base for restrictive transfusion triggers in high-risk patients.

Authors:  Donat R Spahn; Gabriela H Spahn; Philipp Stein
Journal:  Transfus Med Hemother       Date:  2015-03-25       Impact factor: 3.747

5.  Influence of clonidine induced sympathicolysis on anaemia tolerance in anaesthetized pigs.

Authors:  Patrick Lauscher; Harry Kertscho; Malte Krömker; Barbara Haberichter; Kai Zacharowski; Peter Rosenberger; Jens Meier
Journal:  BMC Anesthesiol       Date:  2016-10-12       Impact factor: 2.217

6.  Anemia Is a Novel Predictive Factor for the Onset of Severe Chemotherapy-Induced Peripheral Neuropathy in Lymphoma Patients Receiving Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Therapy.

Authors:  Takashi Saito; Atsuo Okamura; Junichiro Inoue; Daisuke Makiura; Hisayo Doi; Kimikazu Yakushijin; Hiroshi Matsuoka; Yoshitada Sakai; Rei Ono
Journal:  Oncol Res       Date:  2018-05-19       Impact factor: 5.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.